Hi Gekko yes that was the premise of a previous post, i.e., that...

Hi Gekko yes that was the premise of a previous post, i.e., that both of OSL’s current trials are still “active”, OncoPac1 (estimated Jan 2021 completion) and PanCO (est June 2020 completion).

https://clinicaltrials.gov/ct2/results?term=Oncosil&cond=Pancreas+Cancer&draw=1&rank=2#rowId1

Given that many recent (in the last month or so) CE marks were awarded on long completed trials, eg Dianosic intra nasal bleeding device, study completion July 2019, single group assignment, 10 participants no masking...(relevant to OSL)

https://clinicaltrials.gov/ct2/show/NCT03912051?term=Dianosic&cond=Intra+nasal+bleeding&draw=2&rank=1

V-wave already discussed but study completed October 2017, single group assessment , 16 participants, no masking...(relevant to OSL)

https://clinicaltrials.gov/ct2/show/NCT01965015?term=V-wave&cond=Heart+failure&draw=2&rank=2

Keystone Heart “Triguard” study completed June 2019

https://clinicaltrials.gov/ct2/show/NCT02536196?term=Triguard&cond=Cerebral+embolic+protection&draw=2&rank=1

....it is unlikely marking can be categorically considered until relevant studies have been closed off, imo. Of course I would welcome it sooner but would be surprised if this occurred.